How The Kura Oncology (KURA) Narrative Is Shifting With Komzifti Launch And New Analyst Targets [Yahoo! Finance]
Kura Oncology, Inc. (KURA) Discusses Updated Data on Darlifarnib and Cabozantinib Combination in Advanced Renal Cell Carcinoma Transcript [Seeking Alpha]
Kura Oncology Shares Surge Following Positive Kidney Cancer Trial Data [TheStreet.com]
Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib
Kura Oncology (KURA) was upgraded by Lake Street Capital to "strong-buy".